Receptor recognition and cell entry of coronaviruses
冠状病毒的受体识别和细胞进入
基本信息
- 批准号:9174759
- 负责人:
- 金额:$ 46.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-06-07 至 2021-05-31
- 项目状态:已结题
- 来源:
- 关键词:AnimalsAntiviral AgentsAttenuatedBindingBiochemicalBiological AssayBiological ModelsCEACAM1CattleCellsChiropteraCleaved cellComplexCoronavirusDevelopmentDiarrheaDiseaseDisease OutbreaksElectronsEpidemicEvolutionFamilyFamily suidaeFundingFutureGalactose Binding LectinGoalsGrantHealthHomologous GeneHumanInfectionInterventionIntestinesKnowledgeLeadLifeMammalsMembraneMembrane FusionMicroscopicMiddle East Respiratory Syndrome CoronavirusModelingMolecularMolecular ConformationMonitorMusMutationNeuronsPathogenesisPathway interactionsPeptide HydrolasesPlayProcessProtease InhibitorProteinsProteolysisResearchRoleSARS coronavirusSevere Acute Respiratory SyndromeStructureSubunit VaccinesSurfaceTestingTropismViralVirusVirus DiseasesVirus ReceptorsViverridaeanalogbasedesignextracellularinhibitor/antagonistmeetingsneurotropicnovelpreventreceptorreceptor bindingreceptor expressionreverse geneticssugartissue tropismtransmission processvirology
项目摘要
Receptor recognition and cell entry by viruses are two initial and essential steps in viral infection cycles. They are important determinants of viral host ranges, tissue tropisms and pathogenesis, and are primary targets for human intervention. Coronaviruses (CoVs) pose serious health threats to humans and other animals. SARS-CoV and MERS-CoV have infected thousands of people with significant fatality, whereas porcine epidemic diarrhea CoV is currently causing ~100% fatality in piglets. A virus-surface spike protein guides CoV entry into host cells by binding to its host receptor via its S1 subunit and fusing viral and host membranes via its S2 subunit. S1 from different CoVs recognizes a variety of host receptors through one or both of its domains (S1-NTD and S1-CTD), and the S1/S2 boundary is cleaved by host proteases for activation of membrane fusion by S2. Our previous research has determined a number of crystal structures of CoV S1 domains by themselves or in complex with their respective receptor, and also shown how proteolysis regulates the cell entry of some CoVs. Our research has contributed critically to the current knowledge about the molecular mechanisms for CoV receptor recognition, cell entry, and cross-species transmission. In this competitive renewal of R01, we will continue to investigate how CoVs exploit host receptors and host proteases for cell entry. This proposal has three specific aims. Aim 1 examines receptor binding by CoV S1-NTDs. Specifically, we will investigate whether S1-NTDs from different CoV genera have the same structural fold and evolutionary origin as host galectins (galactose-binding lectins). We will also examine how CoV S1-NTDs recognize sugar receptors. These studies will reveal the evolutionary origins of CoV S1-NTDs, enhance understanding of sugar recognition by CoVs, and may facilitate future design of sugar analogues and subunit vaccines to inhibit CoV infections. Aim 2 focuses on receptor binding by CoV S1-CTDs. Specifically, we will analyze the interactions between the S1-CTDs of bat SARS-like CoVs (SL-CoVs) and the protein receptor homologues from humans and other animals, and elucidate how bat SL-CoVs transmitted to humans and other animals to cause the SARS epidemic through evolutionary changes in their S1-CTDs. These studies will provide critical information for understanding emergence potential of bat SL-CoVs and for facilitating epidemic monitoring and control. Aim 3 investigates cell entry by CoVs. Specifically, we will investigate what host proteases activate CoV entry and how the proteases motifs in CoV spikes have evolved to modulate CoV entry. These studies will reveal how host proteases regulate CoV entry to meet their specific need for host range, tissue tropism and pathogenesis, and may facilitate future design of protease inhibitors to block CoV entry. Overall, this proposal investigates the molecular and structural mechanisms for receptor recognition, cell entry, cross-species transmission, and tissue tropism of CoVs, which will lead to novel principles in virology. This research is also important for evaluating the emerging disease potentials of CoVs and for preventing, controlling and treating CoV infections in humans and other animals.
受体识别和病毒进入细胞是病毒感染周期的两个初始和必要步骤。它们是病毒宿主范围、组织趋向性和发病机制的重要决定因素,也是人类干预的主要目标。冠状病毒(CoVs)对人类和其他动物的健康构成严重威胁。SARS-CoV和MERS-CoV已经感染了数千人,死亡率很高,而猪流行性腹泻CoV目前在仔猪中造成约100%的死亡率。病毒表面刺突蛋白通过其S1亚基与宿主受体结合,并通过其S2亚基融合病毒和宿主膜,从而引导冠状病毒进入宿主细胞。来自不同冠状病毒的S1通过其一个或两个结构域(S1- ntd和S1- ctd)识别多种宿主受体,并且S1/S2边界被宿主蛋白酶切割以激活S2的膜融合。我们之前的研究已经确定了冠状病毒S1结构域自身或与其各自受体复合物的许多晶体结构,并显示了蛋白质水解如何调节某些冠状病毒的细胞进入。我们的研究为当前关于冠状病毒受体识别、细胞进入和跨物种传播的分子机制的知识做出了重要贡献。在R01的竞争性更新中,我们将继续研究冠状病毒如何利用宿主受体和宿主蛋白酶进入细胞。这项建议有三个具体目标。目的1检测冠状病毒S1-NTDs与受体的结合。具体来说,我们将研究来自不同冠状病毒属的S1-NTDs是否与宿主半乳糖结合凝集素(半乳糖结合凝集素)具有相同的结构折叠和进化起源。我们还将研究冠状病毒S1-NTDs如何识别糖受体。这些研究将揭示冠状病毒S1-NTDs的进化起源,增强对冠状病毒糖识别的理解,并可能促进未来设计糖类似物和亚单位疫苗来抑制冠状病毒感染。目的2关注冠状病毒S1-CTDs与受体的结合。具体而言,我们将分析蝙蝠SARS样冠状病毒(sl - cov) S1-CTDs与人类和其他动物的蛋白受体同源物之间的相互作用,并阐明蝙蝠sl - cov如何通过其S1-CTDs的进化变化传播给人类和其他动物,从而引起SARS流行。这些研究将为了解蝙蝠sl - cov的出现潜力以及促进流行病监测和控制提供关键信息。目的3研究冠状病毒进入细胞。具体来说,我们将研究哪些宿主蛋白酶激活冠状病毒的进入,以及冠状病毒刺突中的蛋白酶基序如何进化以调节冠状病毒的进入。这些研究将揭示宿主蛋白酶如何调节冠状病毒进入以满足其对宿主范围、组织趋向性和发病机制的特定需求,并可能为未来设计阻断冠状病毒进入的蛋白酶抑制剂提供帮助。总的来说,本研究旨在研究冠状病毒受体识别、细胞进入、跨物种传播和组织趋向性的分子和结构机制,这将为病毒学提供新的原理。这项研究对于评估新出现的冠状病毒疾病潜力以及预防、控制和治疗人类和其他动物的冠状病毒感染也具有重要意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Fang Li其他文献
Fang Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Fang Li', 18)}}的其他基金
Targeting ATM to boost systemic effects of radiotherapy and immunotherapy
靶向 ATM 以增强放射治疗和免疫治疗的全身效应
- 批准号:
10586034 - 财政年份:2021
- 资助金额:
$ 46.44万 - 项目类别:
Targeting apoptotic caspases to enhance cancer radiotherapy
靶向凋亡半胱天冬酶以增强癌症放射治疗
- 批准号:
10305613 - 财政年份:2017
- 资助金额:
$ 46.44万 - 项目类别:
Necroptotic genes in cancer cellular response to radiation
癌细胞对辐射反应中的坏死性凋亡基因
- 批准号:
10089416 - 财政年份:2017
- 资助金额:
$ 46.44万 - 项目类别:
MOUSE HEPATITIS CORONAVIRUS RECEPTOR-BINDING DOMAIN
小鼠肝炎冠状病毒受体结合域
- 批准号:
8361713 - 财政年份:2011
- 资助金额:
$ 46.44万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 46.44万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 46.44万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 46.44万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 46.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 46.44万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 46.44万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 46.44万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 46.44万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 46.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 46.44万 - 项目类别: